Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With IPO Off The Table, Argos Takes $25 Million From VCs

This article was originally published in The Pink Sheet Daily

Executive Summary

The cancer immunotherapy developer withdrew its IPO registration last month, turning instead to insider investors as it prepares for a pivotal Phase III trial on a dendritic cell treatment.

You may also be interested in...



Korea’s Green Gross, Russia’s Pharmstandard Lead $42.5M Argos Financing; Take Local Rights

The personalized immunotherapy developer partnered with Korea’s Green Cross and Russia’s Pharmstandard but avoided giving away major-market rights to its late-stage program in metastatic renal cell carcinoma. If it completes its proposed $60 million Series E round, its Phase III trial will be funded to completion.

Russian, Korean Pharmas Lead $42.5M Argos Financing, Take Local Rights

The personalized immunotherapy developer partnered with two foreign pharmas but avoided giving away major-market rights to its late-stage program in metastatic renal cell carcinoma. If it completes its proposed $60 million Series E round, its Phase III trial will be funded to completion.

Disappointing Provenge Sales Stir Doubts About Demand

Withdrawing sales forecast and suffering a major blow to stock price, Dendreon notes difficulty in reaching community doctors.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074065

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel